Drug-resistant epilepsy drug Ontozry backed by NICE
pharmaphorum
NOVEMBER 16, 2021
NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharma’s Ontozry. Epilepsy affects more than 600,000 people in the UK and for some, seizures can be life-threatening.
Let's personalize your content